CompletedPhase 4

The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed

Pakistan320 participantsStarted 2004-05

Plain-language summary

Terlipressin and Octreotide are two common agents used as adjuvants in the management of variceal bleeding. Both agents have been claimed equivalent to endoscopic therapy in randomized studies. There are no head to head clinical trials of these two agents available in the literature. We aimed to compare the efficacy and safety of Terlipressin and Octreotide in combination with Endoscopic Variceal band Ligation (EVL)in patients presenting with Esophageal Variceal Bleed (EVB).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All cirrhotic patients with upper GI bleed secondary to esophageal varices of 18 years or more of age Exclusion Criteria: * Ulcerative esophagitis, * Mallory Weiss tear, * Bleeding gastric or duodenal ulcers, * Bleeding from gastric varices or portal hypertensive gastropathy and * Upper GI bleed as a result of thrombocytopenia or bleeding diathesis.

What they're measuring

Safety & Efficacy

Timeframe: 5 days

Trial details

NCT IDNCT00534677

SponsorAga Khan University

Sponsor typeOTHER

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Portal Hypertension trials